282 results on '"Kolek, Vitezslav"'
Search Results
2. Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker Analyses
3. Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
4. Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study
5. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
6. Tumor autophagy is associated with survival outcomes in patients with resected non-small cell lung cancer
7. Genetic control of CCL24, POR, and IL23R contributes to the pathogenesis of sarcoidosis
8. Giant lung metastasis of NRAS-mutant melanoma in a 24-year-old patient with a history of BRAF-mutant conventional melanoma harboring Spitzoid morphology: a case report
9. Prognostic and predictive value of loss of nuclear RAD51 immunoreactivity in resected non-small cell lung cancer patients
10. Serum adiponectin level in obstructive sleep apnea: Relation of adiponectin to obesity and long-term continuous positive airway pressure therapy
11. Effect of pirfenidone on lung function decline and survival: 5-yr experience from a real-life IPF cohort from the Czech EMPIRE registry
12. Helsinki by nature: The Nature Step to Respiratory Health
13. Analysis of arterial hypertension pharmacotherapy in patients with obstructive sleep apnea syndrome
14. Prevalence of masked and nocturnal hypertension in patients with obstructive sleep apnea syndrome
15. NAS agar is more suitable than McKay agar for primary culture of Streptococcus milleri group (SMG) fastidious bacteria, S. intermedius in particular
16. Matrix Metalloproteinases and Their Inhibitors in Chronic Obstructive Pulmonary Disease
17. High-Density Genetic Mapping Identifies New Susceptibility Variants in Sarcoidosis Phenotypes and Shows Genomic-driven Phenotypic Differences
18. Prognostic value of Bmi-1 oncoprotein expression in NSCLC patients: a tissue microarray study
19. Prognostic impact of PD-1 and PD-L1 expression in malignant pleural mesothelioma: an international multicenter study
20. A Novel Sarcoidosis Risk Locus for Europeans on Chromosome 11q13.1
21. Simultaneous up-regulation of matrix metalloproteinases 1, 2, 3, 7, 8, 9 and tissue inhibitors of metalloproteinases 1, 4 in serum of patients with chronic obstructive pulmonary disease
22. Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial
23. Full Oral Vinorelbine (NVBO) on D1 and D8 With Carboplatin (CBDCA) as First Line Treatment in Advanced Non-small Cell Lung Cancer (NSCLC) Patients: Preliminary Results of a Prospective Sudy in Nonrandomized Population
24. Efficacy and analgesic use during the therapy of iatrogenic pneumothorax using Pleuralvent™ and Chest Tube (ASPIRATE): A randomised controlled trial protocol
25. Chronotropic incompetence could negatively influence post-operative risk assessment in patients before lung cancer surgery
26. ACE gene variants and sarcoidosis in a Finnish population
27. COMBINATION OF NEOADJUVANT AND ADJUVANT CHEMOTHERAPY IN NONSMALL CELL LUNG CANCER: IS IT POSSIBLE AND EFFECTIVE?
28. Protein Profiles of Bronchoalveolar Lavage Fluid from Patients with Pulmonary Sarcoidosis
29. In vitro pharmacoregulation of CC chemokine ligand 5 and its receptor CCR5 in diffuse lung diseases
30. Expression of Macrophage Inflammatory Protein-3β/CCL19 in Pulmonary Sarcoidosis
31. Human Leukocyte Antigen-DRB1 Position 11 Residues Are a Common Protective Marker for Sarcoidosis
32. Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III randomized trial
33. A comparison of Direct sequencing, Pyrosequencing, High resolution melting analysis, TheraScreen DxS, and the K-ras StripAssay for detecting KRAS mutations in non small cell lung carcinomas
34. Non-small Cell Lung Cancer as a Chronic Disease – A Prospective Study from the Czech TULUNG Registry
35. Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
36. Neurogenic Pulmonary Oedema as a Rare Complication of Epileptic Seizures
37. Respiratory muscle training improves the work of breathing and decreases inspiratory muscle fatigue in patients after lung transplantation
38. Chronotropic incompetence in patients before lung cancer surgery
39. Non-small Cell Lung Cancer as a chronic disease – a prospective study from the Czech TULUNG registry
40. Feasibility and safety evaluation of Simeox airway clearance technique (ACT) in patients with bronchiectasis
41. Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study
42. Comparison of lymphocyte immune phenotypes in bronchoalveolar lavage of non-smoking patients with sarcoidosis and other interstitial lung diseases
43. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
44. A Global Survey on Whole Lung Lavage in Pulmonary Alveolar Proteinosis
45. Chronic Inflammation as a Potential Predictive Factor of Nivolumab Therapy in Non-small Cell Lung Cancer
46. Comparison of analgesic use during pneumothorax treatment using ambulatory device and chest drainage
47. The effect of pulmonary rehabilitation on health-related quality of life in patients with pulmonary sarcoidosis
48. Abstract 2643: Increased copy number ofEGFRgene is an independent outcome predictor in resected non-small cell lung cancer patients treated by adjuvant chemotherapy
49. Expression analysis of extracellular microRNA in bronchoalveolar lavage fluid from patients with pulmonary sarcoidosis
50. Dendritic-cell vaccine (DCVAC) with first line chemotherapy in patients with stage IV NSCLC primary analysis of phase 2, open-label, randomized, multicenter trial.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.